Phinomics is a biomarker platform company that focuses on the discovery and exploitation of extrachromosomal circular DNAs (eccDNAs) in precision medicine. Despite their link to various pathologies, such as cancer progression and drug resistance, eccDNAs have remained inaccessible as biomarkers/targets due to technical and informatic challenges. Phinomics has developed novel technologies, devices, and informatics to unlock the eccDNA genetic and epigenetic codes. At scale, the Phinomics platform will enable effective solutions to unmet needs in healthcare in all circular-DNA-dependent indications.